News Package (VIDEO)

MediaSource

Caption

In a new study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, experts found that survival among patients with a specific biomarker called MGMT promoter methylation more than doubled when treated with specific chemotherapy and radiation.

Credit

Ohio State University Comprehensive Cancer Center

Usage Restrictions

All multimedia is available for free and unrestricted media use with a courtesy to The Ohio State University Comprehensive Cancer Center

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.